Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©. - Wikidata - thesis-toulmin - TriplyDB

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

http://www.wikidata.org/entity/Q30848030

about

The Statin-Associated Muscle Symptom Clinical Index (SAMS-CI): Revision for Clinical Use, Content Validation, and Inter-rater Reliability.Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire).

P2860

Q33665495-17B37429-10A9-4AB9-BD61-5712EF3F560A Q38867819-B814AC40-544B-4F2F-90EE-15E8B8886A75

P2860

Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

http://www.wikidata.org/entity/Q30848030

description

2016 nî lūn-bûn

@nan

2016 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Development and Content Validi ...... essment Questionnaire (SEAQ)©.

@ast

Development and Content Validi ...... essment Questionnaire (SEAQ)©.

@en

type

label

Development and Content Validi ...... essment Questionnaire (SEAQ)©.

@ast

Development and Content Validi ...... essment Questionnaire (SEAQ)©.

@en

prefLabel

Development and Content Validi ...... essment Questionnaire (SEAQ)©.

@ast

Development and Content Validi ...... essment Questionnaire (SEAQ)©.

@en

P1433

Q30848030-47F37E79-D172-4E05-AC83-0A2FB7962E18

P1476

Q30848030-6FD6C4F0-7376-4031-9BFF-45CD2C0199FA

P2093

Q30848030-136350D3-281A-4338-9E7C-11C243CDB3B7

Q30848030-3101FA0E-5E74-426C-BF89-B8658707B10C

Q30848030-6AC5AFA0-727A-49AA-86ED-2EB75BFBE78A

Q30848030-8690686F-25D5-4875-AF49-1540ECC9D2AE

Q30848030-996B2554-62F7-4099-AD4D-9B1AA443E60F

Q30848030-AF5E020F-5A24-4A2F-9533-6E65B78E9749

P2860

Q30848030-054187EA-6E81-4F27-9A48-E8EF1FC60476

Q30848030-0899E911-69D9-4B3F-A375-CB6364A5A061

Q30848030-091ACC2F-EB39-44AA-8ACB-7865AC8B6F20

Q30848030-11810755-FEA4-4826-B424-547446E38705

Q30848030-1235BF87-6824-409F-A8A2-087E9FFBA445

Q30848030-131ADDEC-68A6-4FF3-9579-795C92986106

Q30848030-17CCC5F7-9170-41E0-8D4D-127CDBE00EDD

Q30848030-1982DBDE-B528-4A6D-AFDB-1FE63B5EEA34

Q30848030-1A6EEFCF-6E24-4DCC-977F-421880EF5B3F

Q30848030-1C77B5CE-2302-49F7-A912-B49298B9E461

P2888

Q30848030-D76B6201-A7AE-4633-B764-325FD05F8547

P304

Q30848030-4D53F319-1BE1-4990-A204-E1A8B8A584B9

P31

Q30848030-6CCCD46E-208D-4FE8-A609-386DF7BCB1DA

P356

Q30848030-B1F4BF9E-A5F8-4253-A2A2-F261BC1E69E9

P433

Q30848030-C039FE60-0F8A-4C17-8C8E-DF03438C6101

P478

Q30848030-E6A14039-82CF-4931-919B-3DE44C6D6970

P50

Q30848030-CAB36D28-2DEC-4AD6-8B63-821F8D08BA50

P577

Q30848030-A1CACD24-30D4-47F0-950B-F3BD4F0B19CA

P6179

Q30848030-0F3F30FA-7D62-43E4-97D1-282C9FAED65D

P698

Q30848030-A126215C-7591-4A2E-9C74-33C172A7F1EA

P921

Q30848030-91FDA9B8-1771-49B1-8F8E-58BECF4FF0CB

P932

Q30848030-60826C8F-9E56-492B-99A9-922C94D25380

P356

S40271-016-0211-Y

P1433

The Patient: Patient-Centered Outcomes Research

P1476

Development and Content Validi ...... essment Questionnaire (SEAQ)©.

@en

P2093

Alan L Shields

http://www.w3.org/2001/XMLSchema#string

Andrew Koren

http://www.w3.org/2001/XMLSchema#string

Michael H Davidson

http://www.w3.org/2001/XMLSchema#string

Nina Galipeau

http://www.w3.org/2001/XMLSchema#string

Steven V Edelman

http://www.w3.org/2001/XMLSchema#string

Usha G Mallya

http://www.w3.org/2001/XMLSchema#string

P2860

Heart Disease and Stroke Statistics--2015 Update: A Report From the American Heart Association

How do we improve patient compliance and adherence to long-term statin therapy?

Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

Statin-associated muscular and renal adverse events: data mining of the public version of the FDA adverse event reporting system

Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

Statin-associated lower urinary tract symptoms: data mining of the public version of the FDA adverse event reporting system, FAERS.

Statin safety: an overview and assessment of the data--2005.

Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research.

ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

P2888

s40271-016-0211-y

P304

321-334

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40271-016-0211-Y

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Terry A. Jacobson

P577

2016-12-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1038233167

http://www.w3.org/2001/XMLSchema#string

P698

27981439

http://www.w3.org/2001/XMLSchema#string

P921

P932

5422451

http://www.w3.org/2001/XMLSchema#string